Summary
This study will be conducted in adult participants diagnosed with advanced tumors to
characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS118. This
is a Phase 1/2, multi-center, open-label, multiple-dose, first-in-human study, designed
to systematically assess safety and tolerability, to identify the maximum tolerated dose
(MTD) and/or recommended Phase 2 dose (RP2D) for FS118 in participants with advanced
tumors and to determine the efficacy of FS118 in participants with squamous cell
carcinoma of the head and neck (SCCHN) as monotherapy and in combination with paclitaxel.
In addition to safety, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy
will also be assessed.